Study of 962 patients indicates progressive muscular atrophy is a form of ALS
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Progressive muscular atrophy (PMA) is clinically characterized by signs of lower motor neuron dysfunction and may evolve into amyotrophic lateral sclerosis (ALS). Whether PMA is actually a form of ALS has important consequences clinically and for therapeutic trials. We compared the survival of patients with PMA or ALS to analyze the clinical features that influence survival in PMA.
Methods: We reviewed the medical records of patients with PMA (n = 91) or ALS (n = 871) from our ALS Center and verified survival by telephoning the families or using the National Death Index.
Results: In PMA, patients were more likely to be male (p < 0.001), older (p = 0.007), and lived longer (p = 0.01) than in ALS. Cox model analysis suggested that the risk of death increased with age at onset in both patient groups (p < 0.005). Upper motor neuron (UMN) signs developed in 22% of patients with PMA within 61 months after diagnosis. Demographic and other clinical variables did not differ at diagnosis between those who did or did not develop UMN signs. In PMA, the factors present at diagnosis that predicted shorter survival were greater number of body regions affected, lower forced vital capacity, and lower ALS Functional Rating Scale–Revised score. Noninvasive ventilation and gastrostomy were used frequently in PMA.
Conclusion: Although patients with progressive muscular atrophy (PMA) tended to live longer than those with amyotrophic lateral sclerosis (ALS), shorter survival in PMA is associated with the same risk factors that predict poor survival in ALS. Additionally, PMA is relentlessly progressive, and UMN involvement can occur, as also reported in imaging and postmortem studies. For these reasons, PMA should be considered a form of ALS.
Glossary
- ALS=
- amyotrophic lateral sclerosis;
- ALSFRS-R=
- ALS Functional Rating Scale–Revised;
- CI=
- confidence interval;
- FVC=
- forced vital capacity;
- HR=
- hazard ratio;
- LMN=
- lower motor neuron;
- MND=
- motor neuron disease;
- MRS=
- magnetic resonance spectroscopy;
- NIV=
- noninvasive ventilation;
- PEG=
- percutaneous endoscopic gastrostomy;
- PMA=
- progressive muscular atrophy;
- TMS=
- transcranial magnetic stimulation;
- UMN=
- upper motor neuron.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Study of 962 patients indicates progressive muscular atrophy is a form of ALS
- Ken Ikeda, Department of Neurology, Toho University Omori Medical Center, 6-11-1, Omorinishi, Otaku, Tokyo, 143-8541, Japankeni@med.toho-u.ac.jp
- Yasuo Iwasaki
Submitted March 08, 2010 - Reply from the authors
- Hiroshi Mitsumoto, The Eleanor and Lou Gehrig MDA/ALS Research Center, The Neurological Institute of New York, 710 West 168th Street, New York, NY 10032hm264@columbia.edu
- W. -K. Kim, X. Liu, J. Sandner, M. Pasmantier, J. Andrews, L. P. Rowland
Submitted March 08, 2010 - Study of 962 patients indicates progressive muscular atrophy is a form of ALS
- Roger Pamphlett, The University of Sydney, The Stacey MND Laboratory, The University of Sydney, Australia 2006rogerp@med.usyd.edu.au
Submitted February 25, 2010 - Reply from the authors/ Pamphlett
- Hiroshi Mitsumoto, Eleanor and Lou Gehrig MDA/ALS Research Center, The Neurological Institute of New York, 710 West 168th Street, New York, NY 10032hm264@mail.cumc.columbia.edu
- W. -K. Kim, X. Liu, J. Sandner, M. Pasmantier, J. Andrews, L. P. Rowland
Submitted February 25, 2010
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Clinical features that distinguish PLS, upper motor neuron–dominant ALS, and typical ALSP. H. Gordon, B. Cheng, I. B. Katz et al.Neurology, June 01, 2009 -
Articles
Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron diseaseW.J. Triggs, D. Menkes, J. Onorato et al.Neurology, August 01, 1999 -
Articles
Quantitative objective markers for upper and lower motor neuron dysfunction in ALSH. Mitsumoto, A. M. Uluğ, S. L. Pullman et al.Neurology, April 23, 2007 -
Articles
Diagnosis and progression of ALSHiroshi Mitsumoto et al.Neurology, April 01, 1997